VC-funded Company:
TRex Bio
TRexBio is a clinical-stage biotechnology company discovering and developing immunoregulatory medicines based on tissue Treg biology by leveraging cutting-edge computational biology tools, a focus on human tissue, and deep immunobiology expertise. The company's Deep Biology Platform maps human tissue Treg behavior to disease processes to identify and characterize novel targets for therapeutic intervention in autoimmune and inflammatory diseases. This platform has yielded multiple development candidates for potential first-in-class and best-in-class medicines across TRexBio's own pipeline, as well as with top pharma partners.
Key Contact
Funding Events
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/27/26 | $50,000,000 | Venture |
Affinity Asset Advisors Alexandria Venture Investments Avego Bioscience Capital Balyasny Asset Management Delos Capital Eli Lilly and Company Janus Henderson Investors Johnson & Johnson Development Corporation (JJDC) Pfizer Venture Investments Polaris Partners SV Health Investors | undisclosed |
